Should You Buy BioCryst Pharmaceuticals Inc (BCRX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner long-term investor who is impatient. BCRX is still in a bearish price trend (downtrend structure with SMA_200 > SMA_20 > SMA_5) and is trading below the key pivot (6.84) with nearby support at 6.53/6.34. While analysts are broadly bullish and revenue growth is strong, the heavy recent insider selling and deteriorating YoY EPS/net income trend make the risk/reward unattractive for an immediate entry. Best stance today: HOLD / wait for a clearer trend reversal or a stronger fundamental inflection.
Technical Analysis
Trend is bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), signaling persistent downside momentum. MACD histogram is negative (-0.0444) but contracting, suggesting selling pressure may be easing (early stabilization signal, not a confirmed reversal). RSI(6) at ~39.35 is weak but not deeply oversold, implying downside room still exists. Key levels: Pivot 6.84 (price 6.675 is below it = bearish bias). Near-term support at S1 6.531 then S2 6.34; resistance levels at 7.15 and 7.34. Probabilistic pattern read is mildly positive (next day/week/month odds favor modest gains), but it conflicts with the current bearish trend structure, so follow-through is uncertain.
Analyst Ratings and Price Target Trends
Recent Street trend is mostly positive: H.C. Wainwright raised PT to $32 (Buy) on pediatric approval; Citizens JMP maintained Outperform but trimmed PT to $25 after Q3; Barclays is more cautious with Equal Weight and a $9 PT after Q3. Net takeaway: Wall Street pros emphasize Orladeyo sales trajectory, reimbursement strength, and pipeline optionality; cons center on tempered guidance/earnings variability and more conservative valuation framing from at least one major bank. Current price (~$6.68) sits far below most bullish targets, but the market is not confirming the bull case yet via price trend.
Wall Street analysts forecast BCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCRX is 19.45 USD with a low forecast of 8 USD and a high forecast of 32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast BCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCRX is 19.45 USD with a low forecast of 8 USD and a high forecast of 32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 6.660
Current: 6.660
